Imfinzi (durvalumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The imfinzi (durvalumab) market size has grown rapidly in recent years. It will grow from $3.01 million in 2025 to $3.36 million in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to clinical success of immune checkpoint inhibitors, rising lung cancer prevalence, regulatory approvals in oncology, improved survival outcomes, strong pharmaceutical investment.

The imfinzi (durvalumab) market size is expected to see rapid growth in the next few years. It will grow to $5.11 million in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to expansion into new cancer indications, increased immunotherapy accessibility, growth in oncology clinical trials, rising healthcare oncology spending, development of combination protocols. Major trends in the forecast period include rising adoption of pd-l1 inhibitors, expansion of immunotherapy in lung cancer, growth of combination immuno oncology regimens, increased focus on biomarker driven therapies, broader use across multiple solid tumors.

The increasing incidence of cancer is expected to propel the growth of the Imfinzi (durvalumab) market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells that can invade and damage normal body tissues. The rising incidence of cancer is largely attributed to an aging population, as cancer risk increases with age, along with lifestyle factors such as smoking, poor dietary habits, and obesity, which contribute to higher cancer rates. Imfinzi (durvalumab) is used in cancer treatment by blocking the PD-L1 protein, thereby preventing cancer cells from escaping immune system detection. For instance, in May 2024, according to the National Cancer Institute (NIH), a US-based government agency, there were 18.1 million cancer survivors in the United States in 2022, a number projected to increase to 22.5 million by 2032. Therefore, the growing incidence of cancer is driving the expansion of the Imfinzi (durvalumab) market.

The rise of personalized medicine is expected to drive the growth of the Imfinzi (durvalumab) market going forward. Personalized medicine is a healthcare approach that customizes treatment strategies based on individual patient characteristics, including genetic profile, environment, and lifestyle, to achieve more precise and effective outcomes. The expansion of personalized medicine is driven by advances in genomic technologies, deeper understanding of molecular biology, increased availability of precision diagnostic tools, and growing demand for targeted therapies that improve outcomes while reducing adverse effects. Imfinzi (durvalumab), through its targeted inhibition of the PD-L1 protein, supports personalized medicine by enabling tailored immunotherapy approaches based on specific tumor biology and immune characteristics, thereby improving treatment effectiveness and minimizing unnecessary side effects. For example, according to the Personalized Medicine Coalition, a US-based representative organization, personalized medicines accounted for 34% of new drug approvals by the FDA in 2022, and represented at least 25% of new approvals over the previous eight years. Therefore, the growth of personalized medicine is fueling the Imfinzi (durvalumab) market.

Major companies operating in the Imfinzi (durvalumab) market are focusing on expanding indications, such as perioperative use in combination with chemotherapy, to strengthen their competitive position. For instance, in January 2023, AstraZeneca plc, a UK-based biopharmaceutical company, announced that IMFINZI combined with chemotherapy more than doubled the pathological complete response rate in patients with resectable early-stage gastric and gastroesophageal junction cancers compared to chemotherapy alone. This approach involved a two-phase treatment strategy, including pre-surgical and post-surgical administration, and demonstrated sustained immune activation benefits. This expansion into gastrointestinal cancer indications highlights AstraZeneca’s strategy to broaden its clinical applications and support long-term adoption, although it also introduces regulatory challenges due to the need for additional clinical evidence and health economic assessments for more complex treatment regimens.

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the imfinzi (durvalumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the Imfinzi market by increasing costs related to monoclonal antibody production inputs, sterile injection packaging, and temperature controlled logistics. These impacts are most evident in regions reliant on imported biologics such as asia pacific and eastern europe. Hospital oncology budgets face pricing pressures due to higher acquisition costs. At the same time, tariffs have encouraged regional biologics manufacturing investments. This improves long term supply stability and reduces dependence on global trade routes.

The imfinzi (durvalumab) market research report is one of a series of new reports that provides imfinzi (durvalumab) market statistics, including imfinzi (durvalumab) industry global market size, regional shares, competitors with a imfinzi (durvalumab) market share, detailed imfinzi (durvalumab) market segments, market trends and opportunities, and any further data you may need to thrive in the imfinzi (durvalumab) industry. This imfinzi (durvalumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Imfinzi (durvalumab) is a human monoclonal antibody and an immunotherapy medication developed to inhibit programmed death-ligand 1 (PD-L1), a protein that cancer cells use to evade the immune system. It is indicated for the treatment of several cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.

The main types of Imfinzi (durvalumab) include 2.4 mL injections and 10 mL injections. A 2.4 mL injection refers to a defined volume of the medication supplied in a 2.4 milliliter vial or syringe, commonly used to ensure accurate dosing in clinical treatments or procedures. These formulations are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used for various applications such as locally advanced urothelial carcinoma, metastatic urothelial carcinoma, and others.

The imfinzi (durvalumab) market consists of sales of products including Keytruda, Opdivo, Tecentriq, Libtayo, Bavencio and Emerging PD-1/PD-L1 Inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.